Entrar/Registro  
HOME SPANISH
 
Gaceta Médica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Gaceta Médica de México >Year 2009, Issue 4


Violante-Ortiz R
III. Estrategias de prevención y control ante el incremento de la diabetes tipo 2
Gac Med Mex 2009; 145 (4)

Language: Español
References: 25
Page: 295-298
PDF: 47.66 Kb.


Full text




ABSTRACT

Type 2 diabetes is a public health problem in Mexico; prevention and control measures constitute a priority for the health care sector. This disease can and must be prevented. Recent evidence indicates that it can be delayed or prevented with lifestyle changes or with the use of different therapeutic regimes. Lifestyle changessuch as an increase in physical activity, reduction of calorie intake and saturated fats and increase in fiber consumption- has been an effective strategy among several populations worldwide. The challenge is the long term maintenance of these changes. An intensive lifestyle intervention for a short time can lead to noticeable reductions in diabetes risk even without a later intervention. Although drugs reduce the occurrence of diabetes, they are thought to delay the appearance of the disease. The protective effect is lost within a few weeks after drug use is stopped. Diabetes prevention and control strategies must focus jointly on educational and health strategies such as early screening. Until now, lifestyle interventions are the most powerful tool available for type 2 diabetes prevention in high risk populations.


Key words: Type 2 diabetes, prevention and control measures, lifestyle.


REFERENCIAS

  1. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, Barquera S, Rosas-Peralta M, et al. Las enfermedades crónicas no transmisibles en México: sinopsis epidemiológica y prevención integral. Salud Publica Mex 2008;50:419-426.

  2. International Diabetes Federation. Diabetes Atlas. 2nd edition. Brussels, Belgium: International Diabetes Federation; 2006.

  3. Velázquez-Monroy O, Barinagarrementería-Aldatz F, Rubio-Guerra A, Verdejo J, Méndez-Bello MA, et al. Morbilidad y mortalidad de la enfermedad isquémica del corazón y cerebrovascular en México. Arch Cardiol Mex 2005; 77:31-39.

  4. Buchanan T. Prevention of type 2 diabetes. What is it really? Diabetes Care 2003;26:1306-1308.

  5. Eastman RC, Cowie CC, Harris MI. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk. Diabetes Care 1997;20:127-128.

  6. Saydha SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 2001;24:447-453.

  7. National Diabetes Data Group. Classification and diagnosis of diabetes and other categories of glucose intolerance. Diabetes 1979;28:1039-1057.

  8. World Health Organization. WHO Expert Committee on Diabetes Mellitus: Second Report. Geneva: World Health Organization; 1980.

  9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.

  10. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: reports of a WHO Consultation. Part I. Geneva: World Health Organization; 1999.

  11. Manley SM, Meyer LC, Neil HAW, Ross IS, Turner RC, Holman RR. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. UKPDS 6. Diabetes Res 1990;13:1-11.

  12. Joslin E. The prevention of diabetes mellitus. JAMA 1921;76:79-84.

  13. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten year follow up of subjects with impaired glucose tolerance: Prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-49.

  14. Eriksson KF. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo Feasibility Study. Diabetologia 1991;34:891-898.

  15. Xiao-Ren P. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544.

  16. Tuomilehto J. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.

  17. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:303-403.

  18. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention. A Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67:152-162.

  19. Ramachandran A, Snehalatha C, Mukesh MC, et al. The Indian Diabetes Prevention Programme (IDPP) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance. Diabetologia 2006;49:289-297.

  20. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Laakso M. Acarbose for prevention of type 2 diabetes mellitus. The STOP-NIDDM randomized trial. Lancet 2002;359:2072-2077.

  21. DREAM Trial Investigators. Effects of rosiglitazone on the incidence of diabetes in people with impaired glucose tolerance or impaired fasting glucose. Lancet 2006;368:1096-1105.

  22. Lindstrom J Ilanne-Parikka P. Peltonen N, Aunona S, Ericson JG. The Finish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: the follow up results of the Finish Diabetes Prevention Study. Lancet 2006;238:1673-1679.

  23. Roitman JL, Tuomilehto J. Counterpoint: evidence-based prevention of type 2 diabetes. The power of lifestyle management. Diabetes Care 2007;30:435-438.

  24. Torgerson JS, Hauptman J Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161.

  25. American Diabetes Association and National Institutes of Diabetes and Digestive and Kidney Diseases. Prevention or delay of type 2 diabetes. Diabetes Care 2004;27:S1,S47-S54.






>Journals >Gaceta Médica de México >Year 2009, Issue 4
 

· Journal Index 
· Links 






       
Copyright 2019